Low transthyretin is associated with the poor prognosis of colorectal cancer

被引:0
|
作者
Zhang, Zhe [1 ,2 ,3 ]
Hu, Chenhao [1 ,2 ,3 ]
Shi, Feiyu [1 ,2 ,3 ]
Zhang, Lei [1 ,2 ,3 ]
Wang, Ya [2 ,3 ]
Zhang, Yujie [1 ,2 ,3 ]
Zhang, Xiaojiang [1 ,2 ,3 ]
She, Junjun [1 ,2 ,3 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gen Surg, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Medx Inst, Affiliated Hosp 1, Ctr Gut Microbiome Res, Xian, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept High Talent, Xian, Shaanxi, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2025年 / 15卷
基金
中国国家自然科学基金;
关键词
transthyretin; prognosis; colorectal cancer; clinicopathologic feature; cancer-specific survival; nomogram; MARKER;
D O I
10.3389/fonc.2025.1397019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To determine whether transthyretin (TTR) influences the prognosis of patients with colorectal cancers and establish a predictive model based on TTR. Methods Between January 2013 and February 2019, the clinical data of 1322 CRC patients aged from 18 years to 80 years who underwent surgical treatment were retrospectively analyzed. The preoperative TTR level, clinicopathological data, and follow-up data were recorded. The X-tile program was used to determine the optimal cut-off value. Cox proportional hazard regression analysis was conducted to evaluate the correlation between the TTR and the cumulative incidence of cancer-specific survival (CSS). Nomograms were then developed to predict CSS. Furthermore, an additional cohort of 377 CRC patients enrolled between January 2014 and December 2015 was included as an external validation. Results Based on the optimal cut-off value of 121.3 mg/L, we divided the patients into the TTR-lower group (<121.3 mg/L) and the TTR-higher group (>= 121.3 mg/L). Comparative analysis revealed that the TTR-higher group exhibited a younger demographic, a higher prevalence of low colorectal cancers, an elevated R0 resection rate, superior differentiation, earlier stage and lower levels of carcinoembryonic antigen (CEA) in contrast to the TTR-lower group. The Cox multivariable analysis underscored the significance of TTR and various clinicopathological factors, encompassing age, tumor location, R0 resection status, differentiation grade, disease stage, postoperative chemoradiotherapy, and preoperative CEA levels, as substantial prognostic indicators. The postoperative survival nomogram, when internally and externally assessed, demonstrated commendable performance across multiple metrics, including the area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis (DCA). Compared with other models, the proportional hazards model combined with TTR demonstrates superior performance in terms of C-index, AUC, calibration chart, and DCA within the prognostic column chart. Conclusions The preoperative TTR was identified as a prognostic factor for predicting the long-term prognosis of CRC patients who underwent surgical treatment, supporting its role as a prognostic biomarker in clinical practice.
引用
收藏
页数:15
相关论文
共 50 条
  • [21] Matrix metalloproteinase-13 is associated with poor prognosis in colorectal cancer
    Leeman, MF
    McKay, JA
    Murray, GI
    JOURNAL OF PATHOLOGY, 2001, 195 : 24A - 24A
  • [22] Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer
    Leeman, MF
    McKay, JA
    Murray, GI
    JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (10) : 758 - 762
  • [23] Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis
    Jin, Min
    Fan, Qilin
    Shang, Fumei
    Zhang, Tao
    Ogino, Shuji
    Liu, Hongli
    ONCOLOGY LETTERS, 2024, 27 (05)
  • [24] Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer
    Yamamoto, Hirofumi
    Tei, Mitsuyoshi
    Uemura, Mamoru
    Takemasa, Ichiro
    Uemura, Yoshio
    Murata, Kohei
    Fukunaga, Mutsumi
    Ohue, Masayuki
    Ohnishi, Tadashi
    Ikeda, Kimimasa
    Kato, Takeshi
    Okamura, Shu
    Ikenaga, Masakazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Mizushima, Tsunekazu
    Mimori, Koshi
    Doki, Yuichiro
    Mori, Masaki
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2013, 42 (02) : 549 - 555
  • [25] Yes-associated protein expression is associated with poor prognosis in patients with colorectal cancer
    Cao, Liyu
    Zhang, Cong
    Wu, Qingqing
    Bai, Zhenzhen
    Chen, Jing
    ONCOLOGY LETTERS, 2021, 22 (03)
  • [26] Low PDCD4 Expression Is Associated With Poor Prognosis of Colorectal Carcinoma
    Kim, Joo Young
    Lee, Hojung
    Kim, Eun Kyung
    Lee, Won Mi
    Hong, Young Ok
    Hong, Soon Auck
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (09) : 685 - 692
  • [27] Low expression of centrosomal protein 78(CEP78) is associated with poor prognosis of colorectal cancer patients
    Meifang Zhang
    Tingmei Duan
    Li Wang
    Jianjun Tang
    Rongzhen Luo
    Ruhua Zhang
    Tiebang Kang
    Chinese Journal of Cancer, 2016, 35 (10) : 509 - 517
  • [28] Low expression of centrosomal protein 78 (CEP78) is associated with poor prognosis of colorectal cancer patients
    Zhang, Meifang
    Duan, Tingmei
    Wang, Li
    Tang, Jianjun
    Luo, Rongzhen
    Zhang, Ruhua
    Kang, Tiebang
    CHINESE JOURNAL OF CANCER, 2016, 35 : 62
  • [29] Presence of Fusobacterium nucleatum is associated with poor prognosis of elderly patients with colorectal cancer
    Miyasaka, Toshimitsu
    Yamada, Takeshi
    Kuriyama, Sho
    Sonoda, Hiromichi
    Shinji, Seiichi
    Matsuda, Akihisa
    Ohta, Ryo
    Yonaga, Kazuhide
    Iwai, Takuma
    Takeda, Kohki
    Ueda, Kohji
    Hiroshi
    Yoshida
    CANCER SCIENCE, 2023, 114 : 328 - 328
  • [30] Presence of Fusobacterium nucleatum is associated with poor prognosis of elderly patients with colorectal cancer
    Miyasaka, Toshimitsu
    Yamada, Takeshi
    Kuriyama, Sho
    Sonoda, Hiromichi
    Shinji, Seiichi
    Matsuda, Akihisa
    Ohta, Ryo
    Yonaga, Kazuhide
    Iwai, Takuma
    Takeda, Kohki
    Ueda, Kohji
    Hiroshi
    Yoshida
    CANCER SCIENCE, 2023, 114 : 118 - 118